Background and Objective: Essential hypertension is a multifactorial disease characterized by the interaction of genetic and environmental factors, with genetic factors accounting for 30-50%. Currently, the relevant SNPs identified through genome-wide screening analysis explain only 2-3% of the blood pressure variance. It is suggested that there is a large number of undiscovered genetic variants associated with essential hypertension. The NADH-ubiquinone oxidoreductase core subunit V2 (NDUFV2) is one of the key subunits of mitochondrial respiratory Complex I, which plays an important role in oxidative stress, inflammation, and cell death, and those are associated with endothelial cell damage, vascular remodeling, and hypertension. The study aims to investigate whether the NDUFV2 rs874250 is associated with essential hypertension. Methods: In total of 1437 subjects, were Chinese-Han from Yunnan province, including 824 patients with essential hypertension (378 males and 446 females) and 613 healthy controls (240 males and 373 females). NDUFV2 rs874250 was selected for genotyping and establishing 2 genetic models: a genotypic model (GG vs GA vs AA) and a super-dominant model [GA vs (GG+AA)] for all subjects. Results: In this study, the frequency distribution of genotypes conformed to the HWE test (p>0.05). The super-dominant model was the best genetic model for the rs874250 locus of the NDUFV2 gene. Under the super-dominant model, we found that the distribution frequency of the GA genotype in the essential hypertension group was higher than that in the control group (P<0.05), and the GA genotype was a risk factor for hypertension (OR=1.30, P<0.05). Diastolic blood pressure (DBP) and mean arterial pressure were significantly higher in GA genotype carriers than in GG+GA genotype carriers after correction for sex, age, and BMI (P<0.05). Conclusions: Our study indicated that the NDUFV2 rs874250 is likely to be involved in essential hypertension, especially in diastolic pressure. We postulate that GA genotype may be a risk factor for elevated DBP, which requires further validation.